Chemo Shortage: ‘Paycheck to Paycheck’; Cancer Blood Test Shines; Struggling to Live

Derick Alison
Derick Alison
2 Min Read

The shortage of crucial cancer drugs has eased a bit, but the vast majority of cancer centers are still “living paycheck to paycheck.” (STAT)

Final results from a large clinical trial showed that a multicancer early detection blood test achieved overall accuracy of 97% in patients with no symptoms of cancer, GRAIL announced.

Janssen announced that the combination of amivantamab (Rybrevant) and lazertinib significantly improved progression-free survival (PFS) in advanced EGFR-mutated non-small cell lung cancer as compared with osimertinib (Tagrisso).

NCI researchers reported encouraging preclinical results with a potential “universal” CAR T-cell therapy for blood cancers.

A phase III trial of venetoclax (Venclexta) plus dexamethasone did not significantly improve PFS in previously treated multiple myeloma, according to a statement from AbbVie.

A pivotal trial of the first-in-class menin inhibitor revumenib for acute myeloid leukemia ended early after data showed the trial met prespecified criteria for hematologic response in certain patients with relapsed/refractory disease, Syndax announced.

Nexcella announced a 95% overall response rate in an early-phase trial of relapsed/refractory multiple myeloma treated with the investigational B-cell membrane antigen-targeted CAR T-cell therapy NXC-201.

A phase III trial of pembrolizumab (Keytruda) showed significant improvement in disease-free survival among patients with localized muscle-invasive urothelial cancer or locally advanced urothelial cancer.

A study by Susan G. Komen showed that many low-income women with breast cancer struggle to afford basic living necessities, including housing, transportation, and utilities.

Women should pay attention to unusual symptoms that might indicate inflammatory breast cancer, an especially aggressive form of the disease. (Ohio State University Comprehensive Cancer Center)

A computer game showed promise for relieving chemotherapy-induced peripheral neuropathy in breast cancer survivors. (University of Texas MD Anderson Cancer Center, Cancer)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow

Source link

Share this Article
Leave a comment
adbanner